Bin Yi1, You Hu1, Dongming Zhu1, Jun Yao1, Jian Zhou1, Yi Zhang1, Zhilong He2, Lifeng Zhang1, Zixiang Zhang1, Jian Yang1, Yuchen Tang1, Yujie Huang1, Dechun Li3, Qiuhua Liu4. 1. Department of General Surgery, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, People's Republic of China. 2. Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. 3. Department of General Surgery, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, People's Republic of China. 499486100@qq.com. 4. Department of General Surgery, The First People's Hospital of Zhangjiagang City, No. 68 Jiyang Western Road, Suzhou, People's Republic of China. liusuntian@163.com.
Abstract
BACKGROUND: Rho GDP dissociation inhibitor 2 (RhoGDI2) has been shown to contribute to the aggressive phenotypes of human cancers, such as tumor metastasis and chemoresistance. OBJECTIVE: This study aimed to assess the effects of RhoGDI2 on tumor progression and chemoresistance in pancreatic cancer cells. METHODS: The expression of RhoGDI2 in pancreatic cancer cells was detected by Western blot analysis. Gain-of-function and loss-of-function approaches were done to examine the malignant phenotypes of the RhoGDI2-expressing or RhoGDI2-depleting cells. The correlation between RhoGDI2 and Snail was also analyzed. RESULTS: Differential expression of RhoGDI2 protein in pancreatic cancer cell lines was identified. Gain-of-function and loss-of-function experiments showed that RhoGDI2 induced the malignant phenotypes of pancreatic cancer cells, including proliferation, migration, invasion, and gemcitabine (GEM) chemoresistance. The upregulation of RhoGDI2 stimulated the expression of Snail, resulting in the altered expression of epithelial marker E-cadherin and mesenchymal marker Vimentin, which were characteristics of the tumorigenic activity of epithelial-mesenchymal transition. The expression of RhoGDI2 and Snail was upregulated in clinical tumor samples, and higher expression of RhoGDI2 or Snail was significantly associated with poor patient survival in pancreatic ductal adenocarcinoma (PDAC). CONCLUSION: The findings indicated that RhoGDI2 promoted GEM resistance and tumor progression in pancreatic cancer and that RhoGDI2 might be a potential therapeutic target in patients with PDAC.
BACKGROUND: Rho GDP dissociation inhibitor 2 (RhoGDI2) has been shown to contribute to the aggressive phenotypes of human cancers, such as tumor metastasis and chemoresistance. OBJECTIVE: This study aimed to assess the effects of RhoGDI2 on tumor progression and chemoresistance in pancreatic cancer cells. METHODS: The expression of RhoGDI2 in pancreatic cancer cells was detected by Western blot analysis. Gain-of-function and loss-of-function approaches were done to examine the malignant phenotypes of the RhoGDI2-expressing or RhoGDI2-depleting cells. The correlation between RhoGDI2 and Snail was also analyzed. RESULTS: Differential expression of RhoGDI2 protein in pancreatic cancer cell lines was identified. Gain-of-function and loss-of-function experiments showed that RhoGDI2 induced the malignant phenotypes of pancreatic cancer cells, including proliferation, migration, invasion, and gemcitabine (GEM) chemoresistance. The upregulation of RhoGDI2 stimulated the expression of Snail, resulting in the altered expression of epithelial marker E-cadherin and mesenchymal marker Vimentin, which were characteristics of the tumorigenic activity of epithelial-mesenchymal transition. The expression of RhoGDI2 and Snail was upregulated in clinical tumor samples, and higher expression of RhoGDI2 or Snail was significantly associated with poor patient survival in pancreatic ductal adenocarcinoma (PDAC). CONCLUSION: The findings indicated that RhoGDI2 promoted GEM resistance and tumor progression in pancreatic cancer and that RhoGDI2 might be a potential therapeutic target in patients with PDAC.
Authors: Mansoor Ahmed; Joseph L Sottnik; Garrett M Dancik; Divya Sahu; Donna E Hansel; Dan Theodorescu; Martin A Schwartz Journal: Cancer Cell Date: 2016-09-01 Impact factor: 31.743
Authors: Ivane Abiatari; Tiago DeOliveira; Vachtang Kerkadze; Christian Schwager; Irene Esposito; Nathalia A Giese; Peter Huber; Frank Bergman; Amir Abdollahi; Helmut Friess; Jörg Kleeff Journal: Mol Cancer Ther Date: 2009-06-09 Impact factor: 6.261